% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Khler:142446,
      author       = {K. C. Kähler and C. Blome and A. Forschner and R. Gutzmer
                      and A. Hauschild and L. Heinzerling and E. Livingstone and
                      C. Loquai and T. Müller-Brenne and D. Schadendorf and J.
                      Utikal$^*$ and T. Wagner and M. Augustin},
      title        = {{T}he outweigh of toxicity versus risk of recurrence for
                      adjuvant interferon therapy: a survey in {G}erman melanoma
                      patients and their treating physicians.},
      journal      = {OncoTarget},
      volume       = {9},
      number       = {40},
      issn         = {1949-2553},
      address      = {[S.l.]},
      publisher    = {Impact Journals LLC},
      reportid     = {DKFZ-2019-00166},
      pages        = {2621-26225},
      year         = {2018},
      abstract     = {After more than two decades with interferon alfa-2a and 2b
                      (IFN) as the only approved drugs in the adjuvant setting for
                      melanoma, new treatment approaches like immune checkpoint
                      inhibitors and BRAF-MEK inhibitors improve the progression
                      free survival (PFS) and also the overall survival (OS). We
                      compared physicians' preferences ('utilities') for health
                      states associated with IFN therapy to their patients'
                      preferences. Utilities describe a preference for a specific
                      health state on a scale of 0 (as bad as death) to 1.0
                      (perfect health).We assessed utilities for health states
                      associated with adjuvant IFN using the standard gamble
                      technique in 108 physicians and 130 melanoma patients. Four
                      IFN toxicity scenarios and three outcome scenarios were
                      given to the participants. Both groups were asked for the
                      5-year disease free survival (DFS) they would need to accept
                      the described IFN-related side effects.In both groups,
                      utilities for melanoma relapse were significantly lower than
                      for IFN side effects, showing that toxicity was more
                      acceptable than relapse. Physicians indicated higher
                      utilities for each scenario and needed lower 5-year DFS both
                      in case of mild-to-moderate and severe side effects.
                      Patients were willing to tolerate mild-to-moderate and
                      severe toxicity for a $50\%$ and $75\%$ chance of 5-year
                      DFS, while physicians only required a chance of $40\%$ and
                      $50\%,$ respectively.Both physicians and patients rated
                      melanoma recurrence much lower than even severe IFN side
                      effects. In direct comparison, physicians rated
                      cancer-related scenarios more positively and accepted IFN
                      toxicity for an even lower treatment benefit.},
      cin          = {G300},
      ddc          = {610},
      cid          = {I:(DE-He78)G300-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29899854},
      pmc          = {pmc:PMC5995230},
      doi          = {10.18632/oncotarget.25439},
      url          = {https://inrepo02.dkfz.de/record/142446},
}